Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.

Eli Lilly has unveiled a $27bn investment in US manufacturing facilities as the pharmaceutical industry prepares for the threat of tariffs and mounts a charm offensive aimed at President Donald ...

Spending on older medicines like metformin, used only for diabetes, declined. But that of popular GLP-1 drugs such as Novo ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...

Studies have shown GLP-1 medications have other health benefits, including lowering the risk of certain diseases and addictions, like drinking and smoking.

Man who ‘begged’ NHS for weightloss jabs drops nine stone after going private - Mark Spurr dropped nine stone after starting ...